The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
FortePhest is developing a new technology to combat herbicide-resistant weeds and invasive plants
Subscribe To Our Newsletter & Stay Updated
